CVRx’s stock has risen nearly 20% after the company revealed that its heart failure device is set to be investigated in an ...

CVRx, Inc. a developer of neuromodulation solutions for patients with cardiovascular diseases, announced initiation of the ...

At booth #115, Integer will spotlight its latest advancements in neuromodulation and next-generation miniaturized active implantable medical devices (AIMDs). These innovations are designed to ...

ReShape Lifesciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application on a new Diabetes Neuromodulation system utilizing its vagal nerve block ...

The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under physician oversight.

The FDA has approved ProlivRx, the first prescription, home-based brain neuromodulation therapy, as an adjunctive treatment ...

Neurolief Inc., a medical device company focused on neuromodulation therapies for neuropsychiatric conditions, today ...

The battery-free percutaneous sacral neuromodulation system has comparable efficacy to published rates for traditional sacral neuromodulation devices. The US Food and Drug Administration (FDA) has ...

ReShape Lifesciences® announced the presentation of pre-clinical data for its innovative Diabetes Neuromodulation device at the Minnesota Neuromodulation Symposium. This device employs Hypoglycemia ...

Given the growing interest in non-invasive neuromodulation devices for the central nervous system, the Forum on Neuroscience and Nervous System Disorders hosted a public workshop on March 2-3, 2015 to ...

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.